Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Buparlisib is a brain penetrable pan-PI3K inhibitor.

de Gooijer MC, Zhang P, Buil LCM, Çitirikkaya CH, Thota N, Beijnen JH, van Tellingen O.

Sci Rep. 2018 Jul 17;8(1):10784. doi: 10.1038/s41598-018-29062-w.

2.

Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2.

de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O.

Neoplasia. 2018 Jul;20(7):710-720. doi: 10.1016/j.neo.2018.05.001. Epub 2018 May 28.

3.

ATP-binding cassette transporters limit the brain penetration of Wee1 inhibitors.

de Gooijer MC, Buil LCM, Beijnen JH, van Tellingen O.

Invest New Drugs. 2018 Jun;36(3):380-387. doi: 10.1007/s10637-017-0539-8. Epub 2017 Nov 17.

PMID:
29147815
4.

The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.

de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O.

Int J Cancer. 2018 Jan 15;142(2):381-391. doi: 10.1002/ijc.31052. Epub 2017 Oct 4.

PMID:
28921565
5.

PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.

Lin F, de Gooijer MC, Hanekamp D, Chandrasekaran G, Buil LC, Thota N, Sparidans RW, Beijnen JH, Würdinger T, van Tellingen O.

Clin Cancer Res. 2017 Mar 1;23(5):1286-1298. doi: 10.1158/1078-0432.CCR-16-1276. Epub 2016 Aug 23.

6.

Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.

Loayza-Puch F, Rooijers K, Buil LC, Zijlstra J, Oude Vrielink JF, Lopes R, Ugalde AP, van Breugel P, Hofland I, Wesseling J, van Tellingen O, Bex A, Agami R.

Nature. 2016 Feb 25;530(7591):490-4. doi: 10.1038/nature16982. Epub 2016 Feb 15.

PMID:
26878238
7.

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.

de Gooijer MC, Zhang P, Thota N, Mayayo-Peralta I, Buil LC, Beijnen JH, van Tellingen O.

Invest New Drugs. 2015 Oct;33(5):1012-9. doi: 10.1007/s10637-015-0266-y. Epub 2015 Jul 1.

PMID:
26123925
8.

ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.

Zhang P, de Gooijer MC, Buil LC, Beijnen JH, Li G, van Tellingen O.

Int J Cancer. 2015 Oct 15;137(8):2007-18. doi: 10.1002/ijc.29566. Epub 2015 Apr 24.

9.

ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.

Lin F, de Gooijer MC, Roig EM, Buil LC, Christner SM, Beumer JH, Würdinger T, Beijnen JH, van Tellingen O.

Clin Cancer Res. 2014 May 15;20(10):2703-13. doi: 10.1158/1078-0432.CCR-14-0084. Epub 2014 Mar 19.

10.

In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.

Durmus S, Naik J, Buil L, Wagenaar E, van Tellingen O, Schinkel AH.

Int J Cancer. 2014 Oct 1;135(7):1700-10. doi: 10.1002/ijc.28797. Epub 2014 Mar 4.

11.

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2.

Lin F, Buil L, Sherris D, Beijnen JH, van Tellingen O.

Int J Cancer. 2013 Sep 1;133(5):1222-33. doi: 10.1002/ijc.28126. Epub 2013 Apr 1.

12.

Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.

Lin F, Hoogendijk L, Buil L, Beijnen JH, van Tellingen O.

Eur J Cancer. 2013 May;49(8):2059-64. doi: 10.1016/j.ejca.2012.12.028. Epub 2013 Feb 17.

PMID:
23422148

Supplemental Content

Support Center